Search company, investor...

Immune Response


Series A | IPO

Total Raised


About Immune Response

Developer of AIDS and pediatric vaccines based on Jonas Salks' approach. The company also develops immune modulation and anti-ideotype technology for autoimmune diseases.

Headquarters Location

5935 Darwin Court

Carlsbad, California, 92008,

United States


Missing: Immune Response's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Immune Response's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Immune Response

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immune Response is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Immune Response News

Immune Response to COVID-19 Strengthens Over Time – Important Implications for Vaccine Boosters

Feb 3, 2023

By Oregon Health & Science UniversityFebruary 3, 2023 A new study from researchers at Oregon Health & Science University suggests that immunity to COVID-19 becomes stronger with increasing time between vaccination and infection. These findings have important implications for vaccine recommendations as the pandemic moves towards becoming a constant presence. Study suggests people who have had COVID-19 benefit from vaccination, even if they’ve delayed it. Immunity from COVID-19 appears to gather strength with more time between vaccination and infection, a new laboratory study from researchers at Oregon Health & Science University suggests. The findings carry implications for vaccine recommendations as the pandemic transitions to an endemic state. Researchers measured the antibody response in blood samples for a group of people who gained so-called “hybrid immunity” through two means: either vaccination followed by a breakthrough infection, or by getting vaccinated after contracting COVID-19. They measured the immune response in blood samples of 96 generally healthy OHSU employees and found that the immune response was uniformly stronger the longer the time period between vaccination and infection. The longest interval measured was 404 days. Their findings suggest that vaccine boosters should be spaced no more frequently than a year apart, at least among healthy people. “Longer intervals between natural infection and vaccination appear to strengthen immune response for otherwise healthy people,” said co-senior author Fikadu Tafesse, Ph.D., associate professor of molecular microbiology and immunology in the OHSU School of Medicine. The study came just before an advisory panel for the Food and Drug Administration (FDA) met on Thursday, January 26, to consider the nation’s COVID-19 vaccine strategy going forward. Published in the Journal for Clinical Investigation Insight, the new research is the latest in a series of laboratory discoveries by OHSU scientists revealing a pattern of strengthened immune response through hybrid immunity. Their findings suggest that the magnitude, potency, and breadth of hybrid immune response all increased with a longer time period between exposure to the virus — whether through vaccination or natural infection. This likely is related to the body’s immune response maturing over time, said co-senior author Marcel Curlin, M.D., associate professor of medicine (infectious diseases) in the OHSU School of Medicine and medical director of OHSU Occupational Health. “The immune system is learning,” Curlin said. “If you’re going to amplify a response, what this study tells us is that you might want to boost that response after a longer period of learning rather than early after exposure.” Further, the research team found that it didn’t matter whether someone developed hybrid immunity by getting vaccinated after contracting COVID-19 or after a breakthrough infection following vaccination. Both groups developed an equally potent immune response. The findings suggest long-lasting potency of so-called “memory cells,” the B cells that recognize an invading virus and generate protein antibodies to neutralize the virus and its many variants. The authors write that an ever-growing pool of people who have contracted the SARS-CoV-2 virus stand to benefit from vaccination, even if they’ve delayed it until now. Relying on natural infection alone is a bad idea, “given the risks of severe illness, long-term complications, and death,” the authors write. The researchers say the findings are the latest to point toward the virus evolving to an endemic state. “Our results point to a future where inevitable vaccine breakthrough infections would be expected to help build a reservoir of population-level immunity that can help blunt future waves and reduce the opportunity for further viral evolution,” they write. The researchers cautioned that the immune response was measured in relatively healthy people, and boosters may be advisable on a more frequent basis among vulnerable people who are older or are immunocompromised. Reference: “An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants” by Timothy A. Bates, Hans C. Leier, Savannah K. McBride, Devin Schoen,2 Zoe L. Lyski, David D. Xthona Lee, William B. Messer, Marcel E. Curlin and Fikadu G. Tafesse, 26 January 2023, JCI Insight.

Immune Response Frequently Asked Questions (FAQ)

  • Where is Immune Response's headquarters?

    Immune Response's headquarters is located at 5935 Darwin Court, Carlsbad.

  • What is Immune Response's latest funding round?

    Immune Response's latest funding round is Series A.

  • How much did Immune Response raise?

    Immune Response raised a total of $12.5M.

  • Who are the investors of Immune Response?

    Investors of Immune Response include TPE Boulder, Cable & Howse and D.H. Blair.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.